Board Member
Outlook Therapeutics, Inc. (OTLK)Equibles does not estimate personal net worth.
Get an email with a short summary when Outlook Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get OTLK alertsRobert C. Jahr is recorded as Board Member and CEO at Outlook Therapeutics, Inc. (OTLK). The newest filing on record that lists Robert C. Jahr as Board Member and CEO at Outlook Therapeutics, Inc. (OTLK) is dated January 26, 2026. The proxy statement of Outlook Therapeutics, Inc. reports total compensation of $1,291,757 for Robert C. Jahr in fiscal 2025, including a base salary of $150,000. Disclosed compensation is on record for 2 fiscal years. Robert C. Jahr has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Outlook Therapeutics, Inc. on August 14, 2026. Outlook Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Outlook Therapeutics, Inc. includes Robert Charles Jahr (CEO and Board Member), Faisal G. Sukhtian (Chairman), Kevin Lundquist (CFO) and 7 others.
“We are entering a defining new chapter for Outlook therapeutics. Only three weeks ago, the FDA-approved Latin AVA is the only FDA-approved ophthalmology formulation of Bevacuzumab for the treatment of wet A&D in the United States.”
“We are entering a defining new chapter for Outlook therapeutics. Only three weeks ago, the FDA-approved Latin AVA is the only FDA-approved ophthalmology formulation of Bevacuzumab for the treatment of wet A&D in the United States.”
Start not stated–present
Last confirmed January 26, 2026
Start not stated–present
Last confirmed January 26, 2026
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Outlook Therapeutics, Inc. (OTLK) | President and Chief Executive Officer | $150,000 | $1,291,757 |
| 2024 | Outlook Therapeutics, Inc. (OTLK) | President and Chief Executive Officer | — | — |
